Medically reviewed by Drugs.com. Last updated on July 28, 2020.
Generic name: NEISSERIA MENINGITIDIS GROUP A CAPSULAR OLIGOSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 10ug in 0.5mL; NEISSERIA MENINGITIDIS GROUP C CAPSULAR OLIGOSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 5ug in 0.5mL, NEISSERIA MENINGITIDIS GROUP W-135 CAPSULAR OLIGOSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 5ug in 0.5mL, NEISSERIA MENINGITIDIS GROUP Y CAPSULAR OLIGOSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 5ug in 0.5mL
Dosage form: injection
For intramuscular injection only.
MENVEO is supplied in 2 vials that must be combined prior to administration. Use the MenCYW-135 liquid conjugate vaccine component (Vial 1) to reconstitute the MenA lyophilized conjugate vaccine component (Vial 2) to form MENVEO. Invert the vial and shake well until the vaccine is dissolved and then withdraw 0.5 mL of reconstituted product. Following reconstitution, the vaccine is a clear, colorless solution, free from visible foreign particles. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If any of these conditions exist, MENVEO should not be administered.
Please note that it is normal for a small amount of liquid to remain in the vial following withdrawal of the dose. Discard unused portion.
For intramuscular injection only.
After reconstitution, administer MENVEO immediately or store between 36°F and 77°F (2°C and 25°C) for up to 8 hours. Shake well before using. Do not freeze. Discard reconstituted vaccine if it has been frozen or not used within 8 hours.
Use a separate sterile needle and sterile syringe for each individual. Each dose of MENVEO should be administered as a single 0.5-mL intramuscular injection, preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle (upper arm) in toddlers, adolescents, and adults. Do not administer MENVEO intravenously, subcutaneously, or intradermally.
The dosing schedule is as follows:
Infants Aged 2 Months: MENVEO is to be administered as a 4-dose series at 2, 4, 6, and 12 months of age.
Children Aged 7 through 23 Months: MENVEO is to be administered as a 2-dose series with the second dose administered in the second year of life and at least 3 months after the first dose.
Children Aged 2 through 10 Years: MENVEO is to be administered as a single dose. For children aged 2 through 5 years at continued high risk of meningococcal disease, a second dose may be administered 2 months after the first dose.
Adolescents and Adults Aged 11 through 55 Years: MENVEO is to be administered as a single dose.
Adolescents and Adults Aged 15 through 55 Years: A single booster dose of MENVEO may be administered to individuals who are at continued risk for meningococcal disease if at least 4 years have elapsed since a prior dose of a meningococcal (serogroups A, C, Y, W-135) conjugate vaccine.
More about Menveo (meningococcal conjugate vaccine)
- Side Effects
- During Pregnancy
- Drug Interactions
- Compare Alternatives
- Pricing & Coupons
- En Español
- Drug class: bacterial vaccines
- FDA Approval History
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.